You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Expanding Precision Particle Fabrication Technology for the Widespread Control of

    SBC: ORBIS BIOSCIENCES, INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): This overall goal of this project is to develop a scalable process for fabricating oil encapsulated particles with uniform sizes and physical characteristics that contain oil as a vehicle for delivering hydrophobic drugs. Poorly water soluble active pharmaceutical ingredients (APIs) represent 40% of all new chemical entities discovered by the pharmaceutical ind ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Facile Detection of Soil-Transmitted Helminth Infections

    SBC: Divergence, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to develop a rapid and accurate immunodiagnostic test for detection of soil- transmitted helminths (STHs) that can be used without laboratory infrastructure. Human STH infections from whipworm (Trichuris), roundworm (Ascaris), and hookworms (Necator and Ancylostoma) create a substantial burden to worldwide public h ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. VLP-Based Antibody-Inducing Vaccines for HIV-1

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizin ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizin ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Improved Vaccines for Influenza B Virus

    SBC: ALTRAVAX, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Influenza is a major cause of morbidity and mortality around the world. In the United States, seasonal epidemics of flu occur from late fall to early spring affecting all age groups but with especially high rates of infection in children. Serious illness and death are consequences of influenza infection among the elderly, young children, and individuals with o ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine

    SBC: IMMURX LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The early infiltration by leukocytes into the tumor microenvironment leads to neovascularization, enhanced tumor growth, metastasis and lethality of the host. Notably, leukocytes enable tumor establishment, as suggested early on by Virchow in 1826 and proven more recently by others (e.g. Manning et al, 2007 Clin Ca Res 13:3951; review Wasiuk/Noelle et al. 2009 ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. ChNKG2D-Targeted Cellular Cancer Therapy: Preclinical Toxicology

    SBC: CELDARA MEDICAL, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Cancer is projected to become the leading cause of death worldwide by 2010. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double again, and to triple by 2030. Multiple myeloma (MM) is a particularly deadly type of cancer. In 2008, 19,920 Americans were diagnosed with MM, and 10,690 died. Five-year survival rates are on ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. TCR-less Targeted T Cells Against Cancer

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): This year cancer will become the leading cause of death worldwide. The global burden of cancer doubled between 1975 and 2000. By 2020, it is projected to double again, and to triple by 2030. Ideally, any cancer therapy should be effective (at killing cancerous cells), targeted (i.e. selective, to avoid killing healthy cells), permanent (to avoid relapse and met ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Combination Therapy of Aspirin and Apyrase for Stroke

    SBC: APT THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for most patients. This enzyme strongly inhibits platelet activation and aggregation with modest bleeding risk. We will validate hypothesis that in thromboembolic model of stroke in rats, combination tre ...

    SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Detection of mtDNA Mutations at Zeptomole Sensitivity without PCR

    SBC: GENEPROTECH,INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Mitochondrial disease caused by point mutations in mitochondrial DNA (mtDNA) can be a formidable diagnostic challenge. Because clinical presentation is variable, multisystemic, and mimics many other neurological disorders, ruling out a mtDNA etiology is difficult in patients with suspected myopathies or encephalopathies. Screening for mtDNA mutations that caus ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government